Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc.: Proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. Utilizing this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world that they partnered with Roche / Genentech for development; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer.
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Oncology, Ophthalmology
Investement Strategy
Under the Radar
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Cell Therapy
2173 Salk Avenue
Suite 200
Carlsbad, CA 92008
United States

Company Participants at Lineage Cell Therapeutics KOL Event

  • Brandi Roberts, Chief Financial Officer
  • Brian Culley, CEO/Interim CFO
  • Ioana Hone, Investor Relations

Top 10 Holders of Lineage Cell Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Broadwood Capital, Inc. 20.58 34,935,485 41.22 13F 6/30/22
Greenway Partners LP 4.08 6,874,242 8.11 Stakes 12/31/21
The Vanguard Group, Inc. 3.55 6,031,251 7.12 Funds 8/31/22
Vanguard Group, Inc. (Subfiler) 3.48 5,905,848 6.97 13F 6/30/22
Defender Capital LLC 3.02 5,131,935 6.06 13F 6/30/22
Laurion Capital Management LP 1.43 2,422,367 2.86 13F 6/30/22
British & American Investment Trust Plc (Invt Mgmt) 1.35 2,271,053 2.68 Funds 12/31/21
BlackRock Institutional Trust Co. NA 1.18 1,996,490 2.36 13F 6/30/22
Raffles Associates LP 1.14 1,930,536 2.28 13F 6/30/22
Prescott General Partners LLC 1.09 1,851,851 2.19 13F 6/30/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.